EGFR and Sepsis: EGFRs have been recognised as key targets in anticancer therapy and EGFR inhibitors are increasingly used in the treatment of cancer with no reported renal toxicity, despite such patients being at increased risk of acute renal injury, predominantly due to sepsis.